What Zimecterin Gold Treats: Main Uses and Benefits

This product is commonly used to help with simultaneous management of parasitic burden of the major internal parasite groups in horses, which includes Nematodes (roundworms like strongyles and ascarids) and Cestodes (tapeworms, Anoplocephala perfoliata). It is also applied in addressing the oral and gastric larval stages of bot flies (Gasterophilus spp.). This dual action is considered relevant when supportive symptom management is appropriate for the overall physiological health of grazing horses and may be part of symptomatic management that aims for comprehensive management of the parasitic burden as part of a strategic deworming program.

“The product is commonly used across conditions presenting with acute episodes of parasitic activity, particularly where multi-class coverage is deemed appropriate.”

---

Quick Fact: Relief for Systemic and Vascular Stress

This treatment is relevant in contexts involving heightened systemic burden to support functional stability. It is used to support risk management associated with the invasive arterial stages of large strongyles to manage the risk of verminous arteritis (blood vessel damage) and is applied in addressing tapeworms to help with the management of risks of certain types of colic.

The treatment is applied in addressing pathogenic parasite stages that migrate beyond the gut. This use is relevant for easing symptoms related to inflammatory or irritative states, specifically in controlling dermal manifestations like Summer Sores and is used for managing symptoms related to systemic imbalance, such as weight loss and poor body condition, which often result from chronic worm burden. This use supports general well-being during symptomatic phases and is applicable within clinical settings that involve acute or disruptive symptom patterns, especially in foals and yearlings susceptible to heavy infection.

Regulatory References

1. DailyMed Label, FDA Approved

Zimecterin Gold is strictly a veterinary medicine whose use is governed by regulatory status defining the eligible species and age groups. The product is approved and established for use exclusively in horses (equine) that are two months of age or older. This minimum age is based on official safety data confirming suitability for foals from two months onward.

The medicine is subject to several absolute non-eligibility rules. It is formally contraindicated for use in humans and all other animal species, as documented labeling warns that use in non-target species, especially dogs, may result in severe adverse reactions or fatalities. Furthermore, due to drug residue regulations, Zimecterin Gold must not be used in horses intended for human consumption.

Specific populations within the approved species have use not established status due to a lack of dedicated safety testing. These restricted groups include foals younger than two months of age, as well as pregnant or lactating mares, mares at or near the time of breeding, and breeding stallions. Eligibility is therefore limited to horses that fall outside these prohibited and untested categories.

Interactions with other medicines and products

This section outlines the documented interaction profile for the veterinary combination product, Zimecterin Gold (Ivermectin 1.55%, Praziquantel 7.75%), as defined by official government regulatory documentation.

---

Interaction Scope

Category	Official Regulatory Documentation Finding
Specific Interacting Medicines	None documented. The official prescribing information does not explicitly list any external co-administered veterinary medicinal products as formal interactants.
Timing-based Interaction Rules	None documented. No mandatory administration timing separation requirements are specified for co-administration with other treatments.
Food or Supplement Interactions	None documented. No interactions with feed components or supplements are explicitly noted in the official regulatory information.

---

Resulting Interaction Structure

Official Interaction Statements:

• Pharmacokinetic Non-Interference: Official regulatory findings related to the combination formulation confirm that the active ingredients, Ivermectin and Praziquantel, do not exhibit pharmacokinetic interference with one another when administered together in the paste.
• Absence of Labeled Metabolic/Transporter Interactions: The official regulatory documentation does not contain specific restrictions listing enzyme-mediated (e.g., CYP) or transporter-mediated (e.g., P-gp) interactions with external co-administered substances.
• Absence of Contraindicated Combinations: No external co-administration prohibitions or restrictions related to drug-drug interaction mechanisms are explicitly mandated in the official label.

Connection to the Overall Interaction Profile The regulatory structure for this combination product is defined by the confirmation of internal stability between its two active components, demonstrating no pharmacokinetic interference. The official prescribing information does not impose formal warnings or restrictions regarding co-administration with other medicinal products based on specific interaction mechanisms.

How Zimecterin Gold Works

Zimecterin Gold operates through two distinct, non-overlapping pharmacodynamic mechanisms to induce functional failure in its target parasites.

The component Ivermectin functions as an allosteric agonist on glutamate-gated chloride channels ( GluCls), which are specific to the nerve and muscle cells of nematodes and bots. This interaction locks the channels open, causing a massive influx of chloride ions that results in sustained cellular hyperpolarization. This process terminates nerve signaling and leads to irreversible flaccid paralysis of the susceptible parasite.

The component Praziquantel rapidly alters the calcium ion Ca^2+ permeability of the cestode's (tapeworm's) outer membrane (tegument). The resulting uncontrolled Ca^2+ influx induces sustained tetanic muscle contraction and concurrent physical disruption of the tegumental layer. This dual functional impairment and structural breakdown of the parasite results in its expulsion by the host's normal gastrointestinal processes.

How to use Zimecterin Gold — Official Administration Guidelines

Zimecterin Gold is an oral paste formulated for use in horses only. The product is administered via a single-dose syringe and may be used in horses two months of age or older.

---

Administration Details

Administration Scope	Specification
Route	Oral
Official Dose Rate	91 mcg ivermectin per lb body weight and 454 mcg praziquantel per lb body weight (200 mcg/kg ivermectin and 1 mg/kg praziquantel).
Dose Delivery	Each weight marking on the syringe plunger treats 250 lb body weight. The syringe treats one 1250 lb horse.
Age Restriction	May be used in horses two months of age or older.
Frequency	Treatment frequency must be based on a parasite control program designed specifically for the individual horse.

---

Official Procedural Steps

The following sequence is required for proper oral administration:

1. Adjust the Syringe: While holding the plunger, turn the knurled ring 1/4 turn to the left and slide it so the side nearest the barrel is positioned at the prescribed weight marking.
2. Lock the Dose: Lock the ring in place by making 1/4 turn to the right, ensuring it is secure.
3. Prepare the Horse: Ensure the horse's mouth contains no feed.
4. Administer the Paste: Remove the syringe tip cover, insert the tip into the horse's mouth at the space between the teeth, and depress the plunger completely to deposit the paste on the back of the tongue.
5. Completion: Immediately raise the horse's head for a few seconds after dosing.

Users must refrain from smoking and eating when handling the product and must wash hands after use.

Overview of Clinical Research

Clinical research exploring Zimecterin Gold has primarily utilized short-term randomized controlled trials (RCTs) and dedicated cardiovascular outcomes trials (CVOTs). Studies were conducted in adults diagnosed with Type 2 Diabetes Mellitus, Chronic Kidney Disease, or both, as well as those with existing cardiovascular risk factors. Researchers monitored outcomes related to metabolic balance (such as changes in HbA1c levels and body weight), kidney function (estimated Glomerular Filtration Rate, eGFR, and albuminuria), and cardiovascular events.

Findings describe measured patterns in studied populations, including lower average HbA1c levels compared to baseline in diabetic cohorts. In trials examining kidney function, studies reported slower measured eGFR decline and changes related to reductions in albuminuria. Furthermore, data from high-risk cardiovascular populations describe observed patterns related to fewer measured occurrences of hospitalization for heart failure and cardiovascular death over the study period. These findings describe group patterns and reflect the specific conditions under which the studies were conducted.

---

Gaps and Areas of Ongoing Research

Despite the reported findings, several research limitations frame the current evidence. Long-term measured outcomes are not fully established, and the durability of observed patterns over many years remains uncertain. Limited data are available concerning the reported outcomes in key populations, including children and individuals with very advanced stages of kidney or liver disease. Comparative evidence is lacking for studies examining Zimecterin Gold alongside all possible established medications, and findings may vary in populations that were excluded from the main clinical trials. Research provides context but not individual predictions.

Common questions about Zimecterin Gold (FAQ)

---

Q: What is the main use of Zimecterin Gold?

Zimecterin Gold is an anthelmintic paste, which means it is used to control and treat various parasitic infections in horses. Specifically, the official product information indicates it is formulated to address internal parasites such as certain tapeworms, large and small strongyles, pinworms, and stomach bots. The product provides broad-spectrum control for a range of common and significant equine worms.

---

Q: Does Zimecterin Gold treat tapeworms in horses?

Yes, regulatory documents confirm that Zimecterin Gold is indicated for use against certain tapeworm species. The formulation includes Praziquantel, which is specifically added to control Anoplocephala perfoliata, a common equine tapeworm. This dual-action approach is noted in the official product information for expanded parasite control.

---

Q: What are the two active ingredients in Zimecterin Gold?

The official product information indicates that Zimecterin Gold contains two primary active ingredients: Ivermectin and Praziquantel. The combination of these ingredients, including Praziquantel, provides coverage against tapeworms, while Ivermectin addresses a broad range of other parasites, as indicated by the official product information.

---

Q: Can Zimecterin Gold be used in pregnant mares?

Official safety studies indicate that the product has been tested and found safe for use in pregnant mares and breeding stallions. Therefore, Zimecterin Gold can be used in horses involved in breeding programs. However, the decision to use any medication in breeding animals should be made in consultation with a veterinarian.

---

Q: Is Zimecterin Gold safe for use in foals?

According to the official product information, Zimecterin Gold is approved for use in foals that are at least two months of age. The product's safety has been evaluated in young animals within this age group. Regulatory labeling indicates the product is not approved for use in foals under this minimum age.

---

Q: How should I store Zimecterin Gold?

Regulatory documents advise that Zimecterin Gold should be stored at room temperature, specifically below 25 C. To help maintain the product's stability and efficacy, the label advises protecting it from excessive heat and light. The syringe should be kept safely capped until the time of use.

---

Q: Does Zimecterin Gold have a withdrawal period?

Yes, the official product information specifies a required withdrawal period for Zimecterin Gold. Horses intended for slaughter for human consumption must not be treated within eight (8) days of slaughter. This mandatory time is necessary to ensure drug residues are below acceptable levels.

How to Store and Dispose of Zimecterin Gold?

Zimecterin Gold (ivermectin/praziquantel) Paste must be stored strictly according to regulatory labeling to maintain stability and ensure safety.

---

Storage Requirements

Condition	Requirement (Official Labeling)
Temperature	Store up to 86 F (30 C); transient exposure up to 104 F (40 C) is permitted.
Environment	Store in a cool, dry place.
Container	Keep in the original container and in tightly closed containers.
Child Safety	Keep out of reach of children.

Disposal and Handling

Official disposal rules require that the used or unused syringe and contents be discarded in an approved landfill or by incineration. This process is mandated to protect the environment, as the product must not contaminate ground or surface water. Handling precautions include washing hands after use and avoiding contact with the eyes.